Stephen M Strittmatter

List of Publications by Year
in descending order

250 papers	31,209 citations	3731 89 h-index	4645 170 g-index
257 all docs	257 docs citations	257 times ranked	24381 citing authors

#	Article	IF	Citations
1	Cellular prion protein mediates impairment of synaptic plasticity by amyloid-Î² oligomers. Nature, 2009, 457, 1128-1132.	27.8	1,390
2	Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 2173-2177.	7.1	1,138
3	Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature, 2000, 403, 439-444.	27.8	1,065
4	Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature, 2001, 409, 341-346.	27.8	1,012
5	Plexin-Neuropilin-1 Complexes Form Functional Semaphorin-3A Receptors. Cell, 1999, 99, 59-69.	28.9	757
6	Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature, 1995, 376, 509-514.	27.8	675
7	Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature, 2002, 417, 547-551.	27.8	647
8	Rho Kinase Inhibition Enhances Axonal Regeneration in the Injured CNS. Journal of Neuroscience, 2003, 23, 1416-1423.	3.6	601
9	Alzheimer amyloid-Î² oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nature Neuroscience, 2012, 15, 1227-1235.	14.8	572
10	Experience-Driven Plasticity of Visual Cortex Limited by Myelin and Nogo Receptor. Science, 2005, 309, 2222-2226.	12.6	551
11	Myelin-Associated Glycoprotein as a Functional Ligand for the Nogo-66 Receptor. Science, 2002, 297, 1190-1193.	12.6	528
12	Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer AÎ² Oligomer Bound to Cellular Prion Protein. Neuron, 2013, 79, 887-902.	8.1	485
13	Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin. Neuron, 2010, 68, 654-667.	8.1	465
14	G0 is a major growth cone protein subject to regulation by GAP-43. Nature, 1990, 344, 836-841.	27.8	432
15	Axon Regeneration in Young Adult Mice Lacking Nogo-A/B. Neuron, 2003, 38, 187-199.	8.1	374
16	Memory Impairment in Transgenic Alzheimer Mice Requires Cellular Prion Protein. Journal of Neuroscience, 2010, 30, 6367-6374.	3.6	374
17	Neuronal pathfinding is abnormal in mice lacking the neuronal growth cone protein GAP-43. Cell, 1995, 80, 445-452.	28.9	372
18	Rac1 Mediates Collapsin-1-Induced Growth Cone Collapse. Journal of Neuroscience, 1997, 17, 6256-6263.	3.6	371

#	Article	IF	Citations
19	A Family of Rat CRMP Genes Is Differentially Expressed in the Nervous System. Journal of Neuroscience, 1996, 16, 6197-6207.	3.6	339
20	An Unbiased Expression Screen for Synaptogenic Proteins Identifies the LRRTM Protein Family as Synaptic Organizers. Neuron, 2009, 61, 734-749.	8.1	322
21	Nogo Receptor Antagonism Promotes Stroke Recovery by Enhancing Axonal Plasticity. Journal of Neuroscience, 2004, 24, 6209-6217.	3.6	318
22	Nogo limits neural plasticity and recovery from injury. Current Opinion in Neurobiology, 2014, 27, 53-60.	4.2	318
23	Nogo-66 Receptor Prevents Raphespinal and Rubrospinal Axon Regeneration and Limits Functional Recovery from Spinal Cord Injury. Neuron, 2004, 44, 439-451.	8.1	311
24	Localization of Nogo-A and Nogo-66 Receptor Proteins at Sites of Axonâ€"Myelin and Synaptic Contact. Journal of Neuroscience, 2002, 22, 5505-5515.	3.6	306
25	LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. Molecular Psychiatry, 2007, 12, 1129-1139.	7.9	300
26	Blockade of Nogo-66, Myelin-Associated Glycoprotein, and Oligodendrocyte Myelin Glycoprotein by Soluble Nogo-66 Receptor Promotes Axonal Sprouting and Recovery after Spinal Injury. Journal of Neuroscience, 2004, 24, 10511-10520.	3.6	285
27	Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury?. Nature Reviews Neuroscience, 2006, 7, 603-616.	10.2	284
28	Molecular basis of semaphorin-mediated axon guidance. Journal of Neurobiology, 2000, 44, 219-229.	3.6	283
29	<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice. Annals of Neurology, 2015, 77, 953-971.	5.3	282
30	Delayed Systemic Nogo-66 Receptor Antagonist Promotes Recovery from Spinal Cord Injury. Journal of Neuroscience, 2003, 23, 4219-4227.	3.6	280
31	The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends in Neurosciences, 2003, 26, 193-198.	8.6	277
32	Small Proline-Rich Repeat Protein 1A Is Expressed by Axotomized Neurons and Promotes Axonal Outgrowth. Journal of Neuroscience, 2002, 22, 1303-1315.	3.6	265
33	Neuropilin-1 Extracellular Domains Mediate Semaphorin D/III-Induced Growth Cone Collapse. Neuron, 1998, 21, 1093-1100.	8.1	264
34	Monoclonal antibody production by receptor-mediated electrically induced cell fusion. Nature, 1984, 310, 792-794.	27.8	261
35	Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia. Cell Reports, 2016, 16, 2576-2592.	6.4	253
36	RGM and its receptor neogenin regulate neuronal survival. Nature Cell Biology, 2004, 6, 749-755.	10.3	243

#	Article	IF	Citations
37	Axon Regeneration in the Peripheral and Central Nervous Systems. Results and Problems in Cell Differentiation, 2009, 48, 305-360.	0.7	241
38	Neogenin mediates the action of repulsive guidance molecule. Nature Cell Biology, 2004, 6, 756-762.	10.3	238
39	MAG and OMgp Synergize with Nogo-A to Restrict Axonal Growth and Neurological Recovery after Spinal Cord Trauma. Journal of Neuroscience, 2010, 30, 6825-6837.	3.6	237
40	Functional expression of sodium channel mutations identified in families with periodic paralysis. Neuron, 1993, 10, 317-326.	8.1	226
41	A new role for Nogo as a regulator of vascular remodeling. Nature Medicine, 2004, 10, 382-388.	30.7	220
42	Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging Initiative. Archives of Neurology, 2010, 67, 1370.	4.5	216
43	Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nature Neuroscience, 1998, 1, 487-493.	14.8	212
44	Truncated Soluble Nogo Receptor Binds Nogo-66 and Blocks Inhibition of Axon Growth by Myelin. Journal of Neuroscience, 2002, 22, 8876-8883.	3.6	206
45	Functional Axonal Regeneration through Astrocytic Scar Genetically Modified to Digest Chondroitin Sulfate Proteoglycans. Journal of Neuroscience, 2007, 27, 2176-2185.	3.6	198
46	Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO Journal, 2003, 22, 3291-3302.	7.8	191
47	Toll-Like Receptor 3 Is a Potent Negative Regulator of Axonal Growth in Mammals. Journal of Neuroscience, 2007, 27, 13033-13041.	3.6	191
48	PlexinA1 Autoinhibition by the Plexin Sema Domain. Neuron, 2001, 29, 429-439.	8.1	189
49	Semaphorin3a Enhances Endocytosis at Sites of Receptorâ€“F-Actin Colocalization during Growth Cone Collapse. Journal of Cell Biology, 2000, 149, 411-422.	5.2	186
50	Fibroblast Growth Factor-Inducible-14 Is Induced in Axotomized Neurons and Promotes Neurite Outgrowth. Journal of Neuroscience, 2003, 23, 9675-9686.	3.6	185
51	Extracellular regulators of axonal growth in the adult central nervous system. Philosophical Transactions of the Royal Society B: Biological Sciences, 2006, 361, 1593-1610.	4.0	180
52	The reticulons: a family of proteins with diverse functions. Genome Biology, 2007, 8, 234.	9.6	180
53	Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimerâ€™s disease mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19014-19019.	7.1	179
54	A membrane-targeting signal in the amino terminus of the neuronal protein GAP-43. Nature, 1989, 341, 345-348.	27.8	178

#	Article	IF	Citations
55	Axonal growth therapeutics: regeneration or sprouting or plasticity?. Trends in Neurosciences, 2008, 31, 215-220.	8.6	178
56	P2Y1 purinergic receptors in sensory neurons: contribution to touch-induced impulse generation.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10465-10470.	7.1	174
57	GAP-43 as a plasticity protein in neuronal form and repair. Journal of Neurobiology, 1992, 23, 507-520.	3.6	172
58	Repulsive factors and axon regeneration in the CNS. Current Opinion in Neurobiology, 2001, 11, 89-94.	4.2	170
59	Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nature Medicine, 2014, 20, 590-591.	30.7	169
60	The CRMP Family of Proteins and Their Role in Sema3A Signaling. Advances in Experimental Medicine and Biology, 2007, 600, 1-11.	1.6	168
61	Semaphorin-mediated axonal guidance via Rho-related G proteins. Current Opinion in Cell Biology, 2001, 13, 619-626.	5.4	166
62	Fyn kinase inhibition as a novel therapy for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 8.	6.2	160
63	Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse. BMC Neuroscience, 2010, 11, 130.	1.9	158
64	Brain CRMP Forms Heterotetramers Similar to Liver Dihydropyrimidinase. Journal of Neurochemistry, 1997, 69, 2261-2269.	3.9	146
65	ROCK and Rho: Biochemistry and Neuronal Functions of Rho-Associated Protein Kinases. Neuroscientist, 2007, 13, 454-469.	3.5	145
66	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
67	Transcriptomic taxonomy and neurogenic trajectories of adult human, macaque, and pig hippocampal and entorhinal cells. Neuron, 2022, 110, 452-469.e14.	8.1	142
68	The Nogo-Nogo Receptor Pathway Limits a Spectrum of Adult CNS Axonal Growth. Journal of Neuroscience, 2006, 26, 12242-12250.	3.6	139
69	Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. Neuron, 2017, 95, 281-296.e6.	8.1	131
70	Structural bases for CRMP function in plexin-dependent semaphorin3A signaling. EMBO Journal, 2004, 23, 9-22.	7.8	130
71	A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 35.	6.2	129
72	Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10997-11002.	7.1	128

#	Article	IF	Citations
73	The N-Terminal Domain of Nogo-A Inhibits Cell Adhesion and Axonal Outgrowth by an Integrin-Specific Mechanism. Journal of Neuroscience, 2008, 28, 1262-1269.	3.6	126
74	Alzheimer Precursor Protein Interaction with the Nogo-66 Receptor Reduces Amyloid-Î² Plaque Deposition. Journal of Neuroscience, 2006, 26, 1386-1395.	3.6	123
75	Myelin associated inhibitors: A link between injury-induced and experience-dependent plasticity. Experimental Neurology, 2012, 235, 43-52.	4.1	120
76	Amyloid-Î² induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion, 2013, 7, 37-41.	1.8	114
77	A PDZ Protein Regulates the Distribution of the Transmembrane Semaphorin, M-SemF. Journal of Biological Chemistry, 1999, 274, 14137-14146.	3.4	110
78	Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimerâ€™s disease. Brain, 2016, 139, 526-546.	7.6	110
79	Rho-Associated Kinase II (ROCKII) Limits Axonal Growth after Trauma within the Adult Mouse Spinal Cord. Journal of Neuroscience, 2009, 29, 15266-15276.	3.6	109
80	Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain, 2012, 135, 1794-1818.	7.6	107
81	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology, 2019, 76, 1219.	9.0	107
82	Anatomical Plasticity of Adult Brain Is Titrated by Nogo Receptor 1. Neuron, 2013, 77, 859-866.	8.1	106
83	Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Annals of Neurology, 2006, 60, 540-549.	5.3	105
84	Prion-Protein-interacting Amyloid-Î² Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. Journal of Biological Chemistry, 2015, 290, 17415-17438.	3.4	104
85	Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Molecular and Cellular Neurosciences, 2005, 29, 26-39.	2.2	103
86	Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Molecular and Cellular Neurosciences, 2014, 61, 226-240.	2.2	102
87	Subcutaneous Nogo Receptor Removes Brain Amyloid-Â and Improves Spatial Memory in Alzheimer's Transgenic Mice. Journal of Neuroscience, 2006, 26, 13279-13286.	3.6	99
88	Genetic Variants of Nogo-66 Receptor with Possible Association to Schizophrenia Block Myelin Inhibition of Axon Growth. Journal of Neuroscience, 2008, 28, 13161-13172.	3.6	98
89	Spatial patterns of brain amyloid-Â burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134, 1077-1088.	7.6	97
90	The Role of Nitric Oxide and NMDA Receptors in the Development of Motor Neuron Dendrites. Journal of Neuroscience, 1998, 18, 10493-10501.	3.6	96

#	Article	IF	Citations
91	Reticulon-4A (Nogo-A) Redistributes Protein Disulfide Isomerase to Protect Mice from SOD1-Dependent Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2009, 29, 13850-13859.	3.6	96
92	Release of MICAL Autoinhibition by Semaphorin-Plexin Signaling Promotes Interaction with Collapsin Response Mediator Protein. Journal of Neuroscience, 2008, 28, 2287-2297.	3.6	93
93	Inosine Alters Gene Expression and Axonal Projections in Neurons Contralateral to a Cortical Infarct and Improves Skilled Use of the Impaired Limb. Journal of Neuroscience, 2009, 29, 8187-8197.	3.6	93
94	Combination of NEP 1-40 Treatment and Motor Training Enhances Behavioral Recovery After a Focal Cortical Infarct in Rats. Stroke, 2010, 41, 544-549.	2.0	88
95	Nogo-66 Receptor Antagonist Peptide (NEP1-40) Administration Promotes Functional Recovery and Axonal Growth After Lateral Funiculus Injury in the Adult Rat. Neurorehabilitation and Neural Repair, 2008, 22, 262-278.	2.9	87
96	Recovery from chronic spinal cord contusion after nogo receptor intervention. Annals of Neurology, 2011, 70, 805-821.	5.3	87
97	Liquid and Hydrogel Phases of PrPC Linked to Conformation Shifts and Triggered by Alzheimerâ€™s Amyloid-Î² Oligomers. Molecular Cell, 2018, 72, 426-443.e12.	9.7	87
98	Cartilage Acidic Proteinâ€“1B (LOTUS), an Endogenous Nogo Receptor Antagonist for Axon Tract Formation. Science, 2011, 333, 769-773.	12.6	86
99	LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology. Molecular and Cellular Neurosciences, 2009, 42, 448-457.	2.2	84
100	Mild Cognitive Impairment: Baseline and Longitudinal Structural MR Imaging Measures Improve Predictive Prognosis. Radiology, 2011, 259, 834-843.	7.3	84
101	Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimerâ€™s Mouse Phenotypes. Cell Reports, 2017, 20, 76-88.	6.4	84
102	Targeting the Nogo Receptor to Treat Central Nervous System Injuries. Nature Reviews Drug Discovery, 2003, 2, 872-879.	46.4	80
103	Ibuprofen Enhances Recovery from Spinal Cord Injury by Limiting Tissue Loss and Stimulating Axonal Growth. Journal of Neurotrauma, 2009, 26, 81-95.	3.4	79
104	Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1833-1842.	3.3	79
105	Angiotensin-Converting Enzyme in the Male Rat Reproductive System: Autoradiographic Visualization with [3H]Captopril*. Endocrinology, 1984, 115, 2332-2341.	2.8	77
106	Characterization of Myelin Ligand Complexes with Neuronal Nogo-66 Receptor Family Members. Journal of Biological Chemistry, 2007, 282, 5715-5725.	3.4	77
107	Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimerâ€™s disease mouse model. Alzheimer's Research and Therapy, 2015, 7, 25.	6.2	76
108	Binding Sites for Amyloid-Î² Oligomers and Synaptic Toxicity. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024075.	6.2	76

#	Article	IF	Citations
109	Î²-amyloid oligomers and cellular prion protein in Alzheimerâ€™s disease. Journal of Molecular Medicine, 2010, 88, 331-338.	3.9	75
110	Sac2/INPP5F is an inositol 4-phosphatase that functions in the endocytic pathway. Journal of Cell Biology, 2015, 209, 85-95.	5.2	75
111	RanBPM Contributes to Semaphorin3A Signaling through Plexin-A Receptors. Journal of Neuroscience, 2006, 26, 4961-4969.	3.6	74
112	Inosine Augments the Effects of a Nogo Receptor Blocker and of Environmental Enrichment to Restore Skilled Forelimb Use after Stroke. Journal of Neuroscience, 2011, 31, 5977-5988.	3.6	73
113	Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5063-5068.	7.1	73
114	Identification of Intrinsic Axon Growth Modulators for Intact CNS Neurons after Injury. Cell Reports, 2017, 18, 2687-2701.	6.4	73
115	Cellular prion protein as a receptor for amyloid-Î² oligomers in Alzheimer's disease. Biochemical and Biophysical Research Communications, 2017, 483, 1143-1147.	2.1	72
116	A novel action of collapsin: Collapsin-1 increases antero- and retrograde axoplasmic transport independently of growth cone collapse. Journal of Neurobiology, 1997, 33, 316-328.	3.6	71
117	The Nogo Receptor NgR1 Mediates Infection by Mammalian Reovirus. Cell Host and Microbe, 2014, 15, 681-691.	11.0	71
118	Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5). Journal of Biological Chemistry, 2014, 289, 28460-28477.	3.4	70
119	The neuronal growth cone as a specialized transduction system. BioEssays, 1991, 13, 127-134.	2.5	69
120	Nogo: A Molecular Determinant of Axonal Growth and Regeneration. Neuroscientist, 2001, 7, 377-386.	3.5	69
121	Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathologica, 2017, 133, 785-807.	7.7	67
122	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	2.0	67
123	Chapter 25 Nogo and the Nogo-66 receptor. Progress in Brain Research, 2002, 137, 361-369.	1.4	66
124	Vps10 Family Proteins and the Retromer Complex in Aging-Related Neurodegeneration and Diabetes. Journal of Neuroscience, 2012, 32, 14080-14086.	3.6	65
125	Oligomers of Amyloid Î² Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease. Journal of Biological Chemistry, 2016, 291, 17112-17121.	3.4	65
126	Substance K and substance P as possible endogenous substrates of angiotensin converting enzyme in the brain. Biochemical and Biophysical Research Communications, 1985, 128, 317-324.	2.1	64

#	Article	IF	Citations
127	Cellular Prion Protein Mediates the Toxicity of Î²-Amyloid Oligomers. Archives of Neurology, 2009, 66, 1325-8.	4.5	64
128	Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. PLoS ONE, 2011, 6, e15918.	2.5	64
129	Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Annals of Neurology, 1999, 46, 366-373.	5.3	63
130	Diffusion Tensor Imaging as a Predictor of Locomotor Function after Experimental Spinal Cord Injury and Recovery. Journal of Neurotrauma, 2014, 31, 1362-1373.	3.4	62
131	Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury. Cell and Tissue Research, 2012, 349, 119-132.	2.9	61
132	Plasticity of Intact Rubral Projections Mediates Spontaneous Recovery of Function after Corticospinal Tract Injury. Journal of Neuroscience, 2015, 35, 1443-1457.	3.6	61
133	Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-Î²-Induced Synaptic Dysfunction and Loss. Journal of Neuroscience, 2019, 39, 758-772.	3.6	61
134	Human neuroepithelial stem cell regional specificity enables spinal cord repair through a relay circuit. Nature Communications, 2018, 9, 3419.	12.8	60
135	Excitotoxic Death of a Subset of Embryonic Rat Motor Neurons In Vitro. Journal of Neurochemistry, 1999, 72, 500-513.	3.9	58
136	A Multi-domain Fragment of Nogo-A Protein Is a Potent Inhibitor of Cortical Axon Regeneration via Nogo Receptor 1. Journal of Biological Chemistry, 2011, 286, 18026-18036.	3.4	58
137	Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury. European Journal of Neuroscience, 2005, 22, 587-594.	2.6	57
138	In Vivo Synaptic Density Imaging with ¹¹C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal of Nuclear Medicine, 2019, 60, 1780-1786.	5.0	57
139	A Neutralizing Anti-Nogo66 Receptor Monoclonal Antibody Reverses Inhibition of Neurite Outgrowth by Central Nervous System Myelin. Journal of Biological Chemistry, 2004, 279, 43780-43788.	3.4	56
140	Brainâ€Derived Neurotrophic Factor Induces Excitotoxic Sensitivity in Cultured Embryonic Rat Spinal Motor Neurons Through Activation of the Phosphatidylinositol 3â€Kinase Pathway. Journal of Neurochemistry, 2000, 74, 582-595.	3.9	55
141	Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimerâ€™s Disease: APP/PS1, 3xTgAD, and Tg2576. Journal of Alzheimer's Disease, 2018, 64, 1325-1336.	2.6	55
142	Axonal regeneration induced by blockade of glial inhibitors coupled with activation of intrinsic neuronal growth pathways. Experimental Neurology, 2012, 237, 55-69.	4.1	54
143	Systematic and standardized comparison of reported amyloid-Î² receptors for sufficiency, affinity, and Alzheimer's disease relevance. Journal of Biological Chemistry, 2019, 294, 6042-6053.	3.4	54
144	Go protein-dependent survival of primary accessory olfactory neurons. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14106-14111.	7.1	53

#	Article	IF	Citations
145	Nogo-A Interacts with the Nogo-66 Receptor through Multiple Sites to Create an Isoform-Selective Subnanomolar Agonist. Journal of Neuroscience, 2005, 25, 5298-5304.	3.6	52
146	Neonatal hypoxia suppresses oligodendrocyte Nogo-A and increases axonal sprouting in a rodent model for human prematurity. Experimental Neurology, 2004, 189, 141-149.	4.1	51
147	Conditional Deletion of<i>Prnp</i>Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. Journal of Neuroscience, 2017, 37, 9207-9221.	3.6	45
148	Growth cone neuropilin-1 mediates collapsin-1/sema III facilitation of antero- and retrograde axoplasmic transport. Journal of Neurobiology, 1999, 39, 579-589.	3.6	44
149	Regulating axon growth within the postnatal central nervous system. Seminars in Perinatology, 2004, 28, 371-378.	2.5	44
150	Selective temporal and regional alterations of Nogo-A and small proline-rich repeat protein 1A (SPRR1A) but not Nogo-66 receptor (NgR) occur following traumatic brain injury in the rat. Experimental Neurology, 2006, 197, 70-83.	4.1	44
151	[3H]Captopril binding to membrane associated angiotensin converting enzyme. Biochemical and Biophysical Research Communications, 1983, 112, 1027-1033.	2.1	43
152	Functional Genome-wide Screen Identifies Pathways Restricting Central Nervous System Axonal Regeneration. Cell Reports, 2018, 23, 415-428.	6.4	43
153	Nogo-C is sufficient to delay nerve regeneration. Molecular and Cellular Neurosciences, 2003, 23, 451-459.	2.2	42
154	Genetic Deletion and Pharmacological Inhibition of Nogo-66 Receptor Impairs Cognitive Outcome after Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2010, 27, 1297-1309.	3.4	42
155	Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. Neuropharmacology, 2018, 130, 54-61.	4.1	42
156	Neuronal and Non-Neuronal Collapsin-1 Binding Sites in Developing Chick Are Distinct from Other Semaphorin Binding Sites. Journal of Neuroscience, 1997, 17, 9183-9193.	3.6	41
157	Angiotensin-Converting Enzyme Localized in the Rat Pituitary and Adrenal Glands by [³H]Captopril Autoradiography*. Endocrinology, 1986, 118, 1690-1699.	2.8	40
158	Comprehensive Corticospinal Labeling with<i>mu-crystallin</i>Transgene Reveals Axon Regeneration after Spinal Cord Trauma in<i>ngr1</i>^{â^’/â^’}Mice. Journal of Neuroscience, 2015, 35, 15403-15418.	3.6	40
159	Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. Acta Neuropathologica Communications, 2020, 8, 96.	5.2	39
160	Angiotensin-Converting Enzyme in the Testis and Epididymis: Differential Development and Pituitary Regulation of Isozymes*. Endocrinology, 1985, 117, 1374-1379.	2.8	38
161	Inhibiting poly(ADP-ribosylation) improves axon regeneration. ELife, 2016, 5, .	6.0	38
162	Nogo receptor decoy promotes recovery and corticospinal growth in non-human primate spinal cord injury. Brain, 2020, 143, 1697-1713.	7.6	38

#	Article	IF	Citations
163	Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Science Translational Medicine, 2022, 14, .	12.4	38
164	Functional outcome is impaired following traumatic brain injury in aging Nogo-A/B-deficient mice. Neuroscience, 2009, 163, 540-551.	2.3	36
165	Pyk2 Signaling through Graf1 and RhoA GTPase Is Required for Amyloid-Î² Oligomer-Triggered Synapse Loss. Journal of Neuroscience, 2019, 39, 1910-1929.	3.6	36
166	PlexinA2 limits recovery from corticospinal axotomy by mediating oligodendrocyte-derived Sema6A growth inhibition. Molecular and Cellular Neurosciences, 2012, 50, 193-200.	2.2	35
167	Gene-Silencing Screen for Mammalian Axon Regeneration Identifies Inpp5f (Sac2) as an Endogenous Suppressor of Repair after Spinal Cord Injury. Journal of Neuroscience, 2015, 35, 10429-10439.	3.6	34
168	Optic nerve regeneration screen identifies multiple genes restricting adult neural repair. Cell Reports, 2021, 34, 108777.	6.4	34
169	Intravitreal Delivery of Human NgR-Fc Decoy Protein Regenerates Axons After Optic Nerve Crush and Protects Ganglion Cells in Glaucoma Models. Investigative Ophthalmology and Visual Science, 2015, 56, 1357-1366.	3.3	33
170	Human NgR-Fc Decoy Protein via Lumbar Intrathecal Bolus Administration Enhances Recovery from Rat Spinal Cord Contusion. Journal of Neurotrauma, 2014, 31, 1955-1966.	3.4	32
171	Differential ontogeny of rat brain peptidases: Prenatal expression of enkephalin convertase and postnatal development of angiotensin-converting enzyme. Developmental Brain Research, 1986, 29, 207-215.	1.7	31
172	Differential but Competitive Binding of Nogo Protein and Class I Major Histocompatibility Complex (MHCI) to the PIR-B Ectodomain Provides an Inhibition of Cells. Journal of Biological Chemistry, 2011, 286, 25739-25747.	3.4	31
173	Progressive retinal degeneration and accumulation of autofluorescent lipopigments in Progranulin deficient mice. Brain Research, 2014, 1588, 168-174.	2.2	31
174	Membrane-type Matrix Metalloproteinase-3 Regulates Neuronal Responsiveness to Myelin through Nogo-66 Receptor 1 Cleavage. Journal of Biological Chemistry, 2011, 286, 31418-31424.	3.4	30
175	Enkephalin Convertase Demonstrated in the Pituitary and Adrenal Gland by3HGuanidinoethylmercaptosuccinic Acid Autoradiography: Dehydration Decreases Neurohypophyseal Levels*. Endocrinology, 1985, 117, 1667-1674.	2.8	29
176	Response to Correspondence: Kim etÂal., â€œAxon Regeneration in Young Adult Mice Lacking Nogo-A/B.â€• Neuron 38, 187â€“199. Neuron, 2007, 54, 195-199.	8.1	29
177	PET imaging of mGluR5 in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 15.	6.2	29
178	Nogo Receptor Interacts with Brain APP and Aβ to Reduce Pathologic Changes in Alzheimers Transgenic Mice. Current Alzheimer Research, 2007, 4, 568-570.	1.4	27
179	Rewiring the spinal cord: Direct and indirect strategies. Neuroscience Letters, 2017, 652, 25-34.	2.1	27
180	Rescue of Transgenic Alzheimerâ€™s Pathophysiology by Polymeric Cellular Prion Protein Antagonists. Cell Reports, 2019, 26, 145-158.e8.	6.4	27

#	Article	IF	Citations
181	Enkephalin Convertase in the Gastrointestinal Tract and Associated Organs Characterized and Localized with [3H]Guanidinoethylmercaptosuccinic Acid*. Endocrinology, 1987, 121, 116-126.	2.8	25
182	Rho GTPases and axonal growth cone collapse. Methods in Enzymology, 2000, 325, 473-482.	1.0	25
183	Regenerating nerves follow the road more traveled. Nature Neuroscience, 2002, 5, 821-822.	14.8	25
184	Impediments to eye transplantation: ocular viability following optic-nerve transection or enucleation. British Journal of Ophthalmology, 2009, 93, 1134-1140.	3.9	25
185	Protein Tyrosine Phosphatase Î´ Mediates the Sema3A-Induced Cortical Basal Dendritic Arborization through the Activation of Fyn Tyrosine Kinase. Journal of Neuroscience, 2017, 37, 7125-7139.	3.6	25
186	Antiâ€PrP^C antibody rescues cognition and synapses in transgenic alzheimer mice. Annals of Clinical and Translational Neurology, 2019, 6, 554-574.	3.7	24
187	Regulation of axonal regeneration by the level of function of the endogenous Nogo receptor antagonist LOTUS. Scientific Reports, 2017, 7, 12119.	3.3	23
188	Plexina2 and CRMP2 Signaling Complex Is Activated by Nogo-A-Liganded Ngr1 to Restrict Corticospinal Axon Sprouting after Trauma. Journal of Neuroscience, 2019, 39, 3204-3216.	3.6	23
189	A proteolytic C-terminal fragment of Nogo-A (reticulon-4A) is released in exosomes and potently inhibits axon regeneration. Journal of Biological Chemistry, 2020, 295, 2175-2183.	3.4	23
190	Inhibition of Poly-ADP-Ribosylation Fails to Increase Axonal Regeneration or Improve Functional Recovery after Adult Mammalian CNS Injury. ENeuro, 2016, 3, ENEURO.0270-16.2016.	1.9	22
191	The nociceptin receptor inhibits axonal regeneration and recovery from spinal cord injury. Science Signaling, 2018, 11, .	3.6	21
192	GAP-43 Augmentation of G Protein-Mediated Signal Transduction Is Regulated by Both Phosphorylation and Palmitoylation. Journal of Neurochemistry, 2002, 70, 983-992.	3.9	20
193	LRRTM1-deficient mice show a rare phenotype of avoiding small enclosuresâ€”A tentative mouse model for claustrophobia-like behaviour. Behavioural Brain Research, 2013, 238, 69-78.	2.2	20
194	Early Activation of Experience-Independent Dendritic Spine Turnover in a Mouse Model of Alzheimer's Disease. Cerebral Cortex, 2016, 27, 3660-3674.	2.9	20
195	Quantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging. Molecular Imaging and Biology, 2021, 23, 372-381.	2.6	20
196	A fluorometric assay for angiotensin-converting enzyme activity. Analytical Biochemistry, 1984, 140, 293-302.	2.4	19
197	Modulation of axonal regeneration in neurodegenerative disease. Journal of Molecular Neuroscience, 2002, 19, 117-121.	2.3	19
198	Nogo Receptor Deletion and Multimodal Exercise Improve Distinct Aspects of Recovery in Cervical Spinal Cord Injury. Journal of Neurotrauma, 2010, 27, 2055-2066.	3.4	19

#	Article	IF	Citations
199	Diltiazem Promotes Regenerative Axon Growth. Molecular Neurobiology, 2019, 56, 3948-3957.	4.0	19
200	Functional MRI and other non-invasive imaging technologies: Providing visual biomarkers for spinal cord structure and function after injury. Experimental Neurology, 2008, 211, 324-328.	4.1	17
201	SCISSORâ€"Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol. BMJ Open, 2016, 6, e010651.	1.9	17
202	Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination. Journal of Neuroscience, 2019, 39, 5562-5580.	3.6	16
203	Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy. Molecular Neurodegeneration, 2022, 17, 32.	10.8	15
204	Whole-Exome Sequencing of an Exceptional Longevity Cohort. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1386-1390.	3.6	14
205	NogoA-expressing astrocytes limit peripheral macrophage infiltration after ischemic brain injury in primates. Nature Communications, 2021, 12, 6906.	12.8	14
206	LaurÃ©n et al. reply. Nature, 2010, 466, E4-E5.	27.8	13
207	An activated mutant of the a subunit of Go increases neurite outgrowth via protein kinase C. Developmental Brain Research, 1995, 87, 77-86.	1.7	12
208	Dendrites go up, axons go down. Nature, 2000, 404, 557-559.	27.8	12
209	No association between schizophrenia and polymorphisms of the PlexinA2 gene in Chinese Han Trios. Schizophrenia Research, 2008, 99, 365-366.	2.0	12
210	Characterization of a neutral, divalent cation-sensitive endopeptidase: a possible role in neuropeptide processing. Molecular Brain Research, 1988, 3, 173-181.	2.3	11
211	Axonal branching in lateral olfactory tract is promoted by Nogo signaling. Scientific Reports, 2016, 6, 39586.	3.3	11
212	B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF. Scientific Reports, 2021, 11, 2890.	3.3	11
213	The stress-responsive gene GDPGP1/mcp-1 regulates neuronal glycogen metabolism and survival. Journal of Cell Biology, 2020, 219, .	5.2	11
214	Neuronal Guidance Molecules: Inhibitory and Soluble Factors. Neuroscientist, 1995, 1, 255-258.	3.5	10
215	Spreading of Alzheimer tau seeds is enhanced by aging and template matching with limited impact of amyloid-Î². Journal of Biological Chemistry, 2021, 297, 101159.	3.4	10
216	Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients. Biomarkers, 2009, 14, 414-417.	1.9	9

#	Article	IF	Citations
217	Isolation of Receptor Clones by Expression Screening in Xenopus Oocytes. , 1999, 128, 1-18.		7
218	Lynx for Braking Plasticity. Science, 2010, 330, 1189-1190.	12.6	7
219	Multimodal exercises simultaneously stimulating cortical and brainstem pathways after unilateral corticospinal lesion. Brain Research, 2013, 1538, 17-25.	2.2	7
220	Nogo-A marks motor neuron disease. Annals of Neurology, 2007, 62, 1-2.	5.3	5
221	Delayed amyloid plaque deposition and behavioral deficits in outcrossed AÎ²PP/PS1 mice. Journal of Comparative Neurology, 2013, 521, 1395-1408.	1.6	5
222	Fronto-temporal dementia risk gene <i>TMEM106B</i> has opposing effects in different lysosomal storage disorders. Brain Communications, 2021, 3, fcaa200.	3.3	5
223	PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. Frontiers in Neuroscience, 2022, 16, 787404.	2.8	5
224	Rabphilin3A reduces integrin-dependent growth cone signaling to restrict axon regeneration after trauma. Experimental Neurology, 2022, 353, 114070.	4.1	5
225	Enkephalin convertase: characterization and localization using [3H]guanidinoethylmercaptosuccinic acid. Biochimie, 1988, 70, 57-64.	2.6	3
226	167â€ƒDiffusion Tensor Imaging as a Predictor of Experimental Spinal Cord Injury Severity and Recovery. Neurosurgery, 2013, 60, 175-176.	1.1	3
227	Emerging Mechanisms in Alzheimerâ€™s Disease and Their Therapeutic Implications. Biological Psychiatry, 2018, 83, 298-299.	1.3	3
228	Gene-environment interaction promotes Alzheimer's risk as revealed by synergy of repeated mild traumatic brain injury and mouse App knock-in. Neurobiology of Disease, 2020, 145, 105059.	4.4	2
229	Chronic head injury promotes tau and amyloidâ€beta pathology and accelerates cognitive decline in a humanized knockâ€in model of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047623.	0.8	2
230	Growth cone neuropilin-1 mediates collapsin-1/sema III facilitation of antero- and retrograde axoplasmic transport. , 1999, 39, 579.		2
231	709 Facilitatory effect of collapsin on axoplasmic transport in mouse DRG neurons. Neuroscience Research, 1996, 25, S82.	1.9	1
232	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.	0.8	1
233	Multimodal imaging of synaptic vesicles with a single probe. Cell Reports Methods, 2022, 2, 100199.	2.9	1
234	Promoting the Regeneration of Axons within the Central Nervous System. , 2005, , 433-xviii.		0

#	Article	IF	Citations
235	CNS Axon Regeneration and Nogo. CNS Neuroscience & Therapeutics, 2006, 6, 32-32.	4.0	0
236	The Dawn of Molecular and Cellular Therapies for Traumatic Spinal Cord Injury. , 2007, , 207-220.		0
237	PET Imaging of serotonin transporter as a biomarker for axon damage and regeneration in spinal cord injury. NeuroImage, 2008, 41, T154.	4.2	0
238	Semaphorins and their Receptors in Vertebrates and Invertebrates. , 2010, , 1961-1966.		0
239	Segmentation of rat spinal cord in PET using spatiotemporal information. , 2010, , .		0
240	Protein Tyrosine Phosphatase Î´ dephospholyrates c-Src in Sema3A signaling. Neuroscience Research, 2010, 68, e136.	1.9	0
241	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.8	0
242	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.8	0
243	Elucidating the role of the AD risk factor Pyk2 in tauâ€induced neuronal dysfunction. Alzheimer's and Dementia, 2020, 16, e036625.	0.8	0
244	PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e037792.	0.8	0
245	11Câ€PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043584.	0.8	0
246	Transduction of Inhibitory Signals by the Axonal Growth Cone. , 2000, , 131-153.		0
247	Semaphorins and their Receptors in Vertebrates and Invertebrates. , 2003, , 877-881.		0
248	Role of Cellular Prion Protein in the Amyloid-Î² Oligomer Pathophysiology of Alzheimerâ€™s Disease. , 2013, , 35-48.		0
249	Axonal Regeneration and Recovery From Chronic Central Nervous System Injury. , 2006, , 1165-1172.		0
250	Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFM. Molecular Imaging and Biology, 2022, , 1.	2.6	0